当前位置: X-MOL 学术Mol. Pharmaceutics › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effect of Formulation Additives on Drug Transport through Size-Exclusion Membranes
Molecular Pharmaceutics ( IF 4.9 ) Pub Date : 2018-06-29 00:00:00 , DOI: 10.1021/acs.molpharmaceut.8b00343
Enikő Borbás 1 , Petra Tőzsér 1 , Konstantin Tsinman 2 , Oksana Tsinman 2 , Krisztina Takács-Novák 3 , Gergely Völgyi 3 , Bálint Sinkó 2 , Zsombor K. Nagy 1
Affiliation  

The aim of this research was to investigate the driving force of membrane transport through size-exclusion membranes and to provide a concentration-based mathematical description of it to evaluate whether it can be an alternative for lipophilic membranes in the formulation development of amorphous solid dispersions. Carvedilol, an antihypertensive drug, was chosen and formulated using solvent-based electrospinning to overcome the poor water solubility of the drug. Vinylpyrrolidone–vinyl acetate copolymer (PVPVA64) and Soluplus were used to create two different amorphous solid dispersions of the API. The load-dependent effect of the additives on dissolution and permeation through regenerated cellulose membrane was observed by a side-by-side diffusion cell, μFLUX. The solubilizing effect of the polymers was studied by carrying out thermodynamic solubility assays. The supersaturation ratio (SSR, defined as the ratio of dissolved amount of the drug to its thermodynamic solubility measured in exactly the same medium) was found to be the driving force of membrane transport in the case of size-exclusion membranes. Although the transport through lipophilic and size-exclusion membranes is mechanistically different, in both cases, the driving force of membrane transport in the presence of polymer additives was found to be the same. This finding may enable the use of size-exclusion membranes as an alternative to lipid membranes in formulation development of amorphous solid dispersions.

中文翻译:

制剂添加剂对药物通过尺寸排阻膜转运的影响

这项研究的目的是研究膜通过尺寸排阻膜运输的驱动力,并为其提供基于浓度的数学描述,以评估其在无定形固体分散体配方开发中是否可以替代亲脂膜。选择了抗高血压药卡维地洛,并使用基于溶剂的静电纺丝技术对其进行配制,以克服该药物不良的水溶性。乙烯基吡咯烷酮-乙酸乙烯酯共聚物(PVPVA64)和Soluplus用于创建API的两种不同的无定形固体分散体。通过并排扩散池μFLUX观察到添加剂对通过再生纤维素膜的溶解和渗透的负载依赖性作用。通过进行热力学溶解度试验研究了聚合物的增溶作用。在尺寸排阻膜的情况下,发现过饱和率(SSR,定义为药物的溶解量与其在完全相同的介质中测得的热力学溶解度之比)是膜运输的驱动力。尽管通过亲脂性和尺寸排阻膜的转运在机械上是不同的,但是在两种情况下,发现在存在聚合物添加剂的情况下,膜转运的驱动力是相同的。该发现可以使得在无定形固体分散体的制剂开发中可以使用尺寸排阻膜作为脂质膜的替代物。在尺寸排阻膜的情况下,被定义为药物溶解量与在完全相同的介质中测得的药物的热力学溶解度之比的定义为膜运输的驱动力。尽管通过亲脂性和尺寸排阻膜的转运在机械上是不同的,但是在两种情况下,发现在存在聚合物添加剂的情况下,膜转运的驱动力是相同的。该发现可以使得在无定形固体分散体的制剂开发中可以使用尺寸排阻膜作为脂质膜的替代物。在尺寸排阻膜的情况下,被定义为药物溶解量与在完全相同的介质中测得的药物的热力学溶解度之比的定义为膜运输的驱动力。尽管通过亲脂性和尺寸排阻膜的转运在机械上是不同的,但是在两种情况下,发现在存在聚合物添加剂的情况下,膜转运的驱动力是相同的。该发现可以使得在无定形固体分散体的制剂开发中可以使用尺寸排阻膜作为脂质膜的替代物。发现在存在聚合物添加剂的情况下膜运输的驱动力是相同的。该发现可以使得在无定形固体分散体的制剂开发中可以使用尺寸排阻膜作为脂质膜的替代物。发现在存在聚合物添加剂的情况下膜运输的驱动力是相同的。该发现可以使得在无定形固体分散体的制剂开发中可以使用尺寸排阻膜作为脂质膜的替代物。
更新日期:2018-06-29
down
wechat
bug